Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients

Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients

Tacrolimus, a calcineurin inhibitor, is widely used to prevent allograft rejection in kidney transplant recipients. Its metabolism is predominantly mediated by the cytochrome P450 3A5 (CYP3A5) enzyme, and single nucleotide variants (SNVs) within intron 3 of the CYP3A5 gene are strongly associated wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Lesly Yanira Xajil-Ramos, Jesús Alonso Gándara-Mireles, Rodrigo José Vargas Rosales, Oscar Kevin Sánchez García, Andrea Mariela Ruano Toledo, Amy Kateleen Aldana de la Cruz, Ismael Lares-Asseff, Leslie Patrón-Romero, Horacio Almanza-Reyes, Randall Lou-Meda
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
CYP3A5
kidney transplant recipients
pharmacokinetics
tacrolimus
pharmacogenetics
acute rejection
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1592134/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1592134/full

Similar Items